Service Category: Slider

Single-gene analysis of KRAS, NRAS, EGFR, BRAF, and other biomarkers for the optimization of tailored cancer treatment.

The new prime DX® technology for molecular tumor profiling is compatible with both FFET and PLASMA and in combination (COMBO)for more holistic analysis

Multigene Liquid Biopsy Test for postmenopausal women with recurrent or metastatic ER+, HER2- breast cancer

In order to find patients who may benefit from PARP inhibitor treatment, the BRCA Somatic test looks for both hereditary and non-inherited mutations in the BRCA1 and BRCA2 genes.

This assay improves the prediction of a patient’s response to immunotherapy across various cancer types and assists the physician in selecting the most suitable personalized treatment.

The Com.pl.it DX® Colon multi-gene test encompasses genes with mutations linked to colorectal cancer. Analyzing many genes is crucial for devising a personalized therapy strategy for colorectal cancer patients.